Severe COVID-19 Associated With Liver Injury in Patients Without Preexisting Liver Disease.
ast (aspartate aminotransferase)
covid-19
liver function tests
liver injury
severity of disease
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
26 Apr 2021
26 Apr 2021
Historique:
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
6
2021
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) is known to disturb liver function tests (LFTs). Not much literature is available regarding the effect of COVID-19 on LFTs in patients without preexisting liver disease. The study aimed to find the effect of COVID-19 in these patients. This was a single-center, observational study with 142 patients who were admitted with COVID-19 during three months. Seven patients were excluded due to the presence of chronic liver disease. Results: A total of 135 patients were included in the study aged between 18 and 95 years (mean 57.7 ± 15.6); among them, 93 were males (68.9%). Hypertension was present in 74 patients (54.8%), and diabetes was present in 48 patients (35.6%). Fever was the chief complaint in 112 patients (83%), followed by dyspnea in 93 patients (68.9%) and cough in 79 patients (58.5%). Elevated aspartate aminotransferase (AST) was seen in 35 patients (26%), gamma-glutamyl transferase (GGT) in 43 patients (32%), alanine transaminase (ALT) in 18 patients (24%), alkaline phosphatase in 19 patients (14%), bilirubin in six patients (4%), and low albumin in 27 patients (20%). Severe COVID-19, when compared with mild to moderate disease, was associated with elevated AST > two-time upper limit normal (2ULN) (p = 0.002), GGT > 2ULN (0.026), and lower albumin (p = 0.020), higher systemic inflammatory response syndrome (SIRS) (0.045), raised procalcitonin (p = 0.045), higher ferritin (p = 0.005), lower pO2 (p = 0.044), and higher Sequential Organ Failure Assessment score (SOFA) (p = 0.002) pointing to the inflammatory response as cause of liver injury. Factors predicting mortality with COVID-19 were assessed, which showed that direct bilirubin (p = 0.001), low albumin (p = 0.013), tachypnea (0.002), and leukocytosis (<0.001) were independently associated with increased COVID-19-related mortality. Patients suffering from COVID-19 have evidence of liver injury, which appears to be secondary to an inflammatory response that correlates with the severity of COVID-19.
Identifiants
pubmed: 34055545
doi: 10.7759/cureus.14705
pmc: PMC8155735
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e14705Informations de copyright
Copyright © 2021, Altaf et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
Cell Discov. 2020 Feb 24;6:11
pubmed: 32133153
Liver Int. 2020 Jul;40(7):1787-1788
pubmed: 32304343
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
Cureus. 2020 Jul 31;12(7):e9487
pubmed: 32879813
Gastroenterology. 2020 Aug;159(2):768-771.e3
pubmed: 32376408
Hepatology. 2020 Oct;72(4):1169-1176
pubmed: 32725890
Front Med (Lausanne). 2020 Nov 09;7:598870
pubmed: 33240911
Hepatology. 2007 Jan;45(1):230-41
pubmed: 17187426
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Antioxid Redox Signal. 2020 Jun 22;:
pubmed: 32524832
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Gastroenterology. 2020 Aug;159(2):739-758.e4
pubmed: 32247018
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Hepatol Int. 2020 Sep;14(5):690-700
pubmed: 32623632
Postgrad Med J. 2020 Nov 12;:
pubmed: 33184141
Intern Emerg Med. 2020 Nov;15(8):1485-1499
pubmed: 32970246